Characterization of 2 Different Prothrombin Complex Concentrates by Different Hemostatic Assays in an In Vitro Hemodilution Model.
Journal
Anesthesia and analgesia
ISSN: 1526-7598
Titre abrégé: Anesth Analg
Pays: United States
ID NLM: 1310650
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
20
8
2022
medline:
26
10
2022
entrez:
19
8
2022
Statut:
ppublish
Résumé
Viscoelastically guided coagulation factor concentrate-based algorithms for the treatment of trauma-induced coagulopathy include the administration of prothrombin complex concentrates (PCCs). However, the exact role of PCC preparations in this context is a matter of debate. Particularly, the ideal diagnostic trigger for their administration and potential differences between heparin-containing and heparin-free preparations remain unclear. We investigated the hypothesis that 2 different PCCs might have distinct influences on in vitro blood coagulation. We conducted a direct comparison of 2 commercially available PCC preparations (the heparin-containing Beriplex P/N and the heparin-free Cofact) in an in vitro hemodilution model. Sole fibrinogen substitution served as the control group. To characterize the hemostatic changes, we utilized conventional coagulation tests, a thrombin generation assay (TGA), and 2 different viscoelastic hemostatic assays (VHAs; ROTEM delta and ClotPro). Irrespective of the diagnostic assay used, no significant differences between the 2 PCC groups were observed. Fibrinogen levels remained stable from the baseline throughout every dilution level. The control group already showed an increased endogenous thrombin potential (ETP; nM·L -1 ·min -1 ) at all dilution levels compared to baseline (baseline, 2829.4 (432.8); 40% dilution, 4211.7 (391.6); 60% dilution, 4290.9 (300.8); 80% dilution, 3861.4 (303.5); all P < .001). Spiking with both PCC preparations led to a further-pronounced thrombin elevation in comparison to the control group (ETP at 40% dilution, PCC1: 4913.3 [370.2], PCC2: 4988.1 [265.7]; 60% dilution, PCC1: 5174.5 [234.7], PCC2: 5390.4 [334.9]; 80% dilution, PCC1: 5253.8 [357.9], PCC2: 5392.6 [313.4]; all P < .001). Conventional coagulation tests did not mirror the TGA results. Despite increased thrombin generation, prothrombin time was significantly prolonged at all dilution levels for the control group, and both PCC groups exhibited significant prolongations at the 60% and 80% dilution levels (all P < .001) compared to baseline. Similarly, VHA did not depict the thrombin elevation. Furthermore, descriptive analyses revealed relevant differences between the 2 VHA devices, particularly at baseline. Both PCC preparations (ie, irrespective of heparin content) induced significant elevation of thrombin generation, which was not depicted by conventional coagulation tests or VHA. Our in vitro results suggest that diagnostic assays routinely used to guide PCC administration might not adequately reflect thrombin generation in bleeding patients.
Sections du résumé
BACKGROUND
Viscoelastically guided coagulation factor concentrate-based algorithms for the treatment of trauma-induced coagulopathy include the administration of prothrombin complex concentrates (PCCs). However, the exact role of PCC preparations in this context is a matter of debate. Particularly, the ideal diagnostic trigger for their administration and potential differences between heparin-containing and heparin-free preparations remain unclear. We investigated the hypothesis that 2 different PCCs might have distinct influences on in vitro blood coagulation.
METHODS
We conducted a direct comparison of 2 commercially available PCC preparations (the heparin-containing Beriplex P/N and the heparin-free Cofact) in an in vitro hemodilution model. Sole fibrinogen substitution served as the control group. To characterize the hemostatic changes, we utilized conventional coagulation tests, a thrombin generation assay (TGA), and 2 different viscoelastic hemostatic assays (VHAs; ROTEM delta and ClotPro).
RESULTS
Irrespective of the diagnostic assay used, no significant differences between the 2 PCC groups were observed. Fibrinogen levels remained stable from the baseline throughout every dilution level. The control group already showed an increased endogenous thrombin potential (ETP; nM·L -1 ·min -1 ) at all dilution levels compared to baseline (baseline, 2829.4 (432.8); 40% dilution, 4211.7 (391.6); 60% dilution, 4290.9 (300.8); 80% dilution, 3861.4 (303.5); all P < .001). Spiking with both PCC preparations led to a further-pronounced thrombin elevation in comparison to the control group (ETP at 40% dilution, PCC1: 4913.3 [370.2], PCC2: 4988.1 [265.7]; 60% dilution, PCC1: 5174.5 [234.7], PCC2: 5390.4 [334.9]; 80% dilution, PCC1: 5253.8 [357.9], PCC2: 5392.6 [313.4]; all P < .001). Conventional coagulation tests did not mirror the TGA results. Despite increased thrombin generation, prothrombin time was significantly prolonged at all dilution levels for the control group, and both PCC groups exhibited significant prolongations at the 60% and 80% dilution levels (all P < .001) compared to baseline. Similarly, VHA did not depict the thrombin elevation. Furthermore, descriptive analyses revealed relevant differences between the 2 VHA devices, particularly at baseline.
CONCLUSIONS
Both PCC preparations (ie, irrespective of heparin content) induced significant elevation of thrombin generation, which was not depicted by conventional coagulation tests or VHA. Our in vitro results suggest that diagnostic assays routinely used to guide PCC administration might not adequately reflect thrombin generation in bleeding patients.
Identifiants
pubmed: 35984000
doi: 10.1213/ANE.0000000000006174
pii: 00000539-202211000-00018
doi:
Substances chimiques
prothrombin complex concentrates
37224-63-8
Hemostatics
0
Thrombin
EC 3.4.21.5
Blood Coagulation Factors
0
Heparin
9005-49-6
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1040Informations de copyright
Copyright © 2022 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
Conflicts of Interest: See Disclosures at the end of the article.
Références
MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55:39–44.
Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127–1130.
Gratz J, Oberladstätter D, Schöchl H. Trauma-induced coagulopathy and massive bleeding: current hemostatic concepts and treatment strategies. Hamostaseologie. 2021;41:307–315.
Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13:680–685.
Coats TJ, Brazil E, Heron M, MacCallum PK. Impairment of coagulation by commonly used resuscitation fluids in human volunteers. Emerg Med J. 2006;23:846–849.
Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg. 2011;113:1003–1012.
Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost. 2007;5:289–295.
Gratz J, Güting H, Thorn S, et al. Protocolised thromboelastometric-guided haemostatic management in patients with traumatic brain injury: a pilot study. Anaesthesia. 2019;74:883–890.
Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol. 2017;34:332–395.
Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23:98.
Hagemo JS, Næss PA, Johansson P, et al. Evaluation of TEG(®) and RoTEM(®) inter-changeability in trauma patients. Injury. 2013;44:600–605.
Infanger L, Dibiasi C, Schaden E, et al. Comparison of the new viscoelastic coagulation analyzer ClotPro® With ROTEM® delta and conventional coagulation tests in critically ill patients with COVID-19. Front Med (Lausanne). 2021;8:777145.
Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma. 2008;64:1177–1182.
McQuilten ZK, Crighton G, Brunskill S, et al. Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review. Transfus Med Rev. 2018;32:6–15.
Stein P, Kaserer A, Sprengel K, et al. Change of transfusion and treatment paradigm in major trauma patients. Anaesthesia. 2017;72:1317–1326.
Gratz J, Schlimp CJ, Honickel M, Hochhausen N, Schöchl H, Grottke O. Sufficient thrombin generation despite 95% hemodilution: an in vitro experimental study. J Clin Med. 2020;9:E3805.
Gratz J, Ponschab M, Iapichino GE, et al. Comparison of fresh frozen plasma vs. coagulation factor concentrates for reconstitution of blood: an in vitro study. Eur J Anaesthesiol. 2020;37:879–888.
Brinkman HJ, Patiwael S, Tripathi S, Meijers JC. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: an in vitro evaluation. Thromb Res. 2016;139:102–110.
Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224–232.
Wiegele M, Infanger L, Lacom C, Koch S, Baierl A, Schaden E. Thrombin generation and platelet function in ICU patients undergoing CVVHD using regional citrate anticoagulation. Front Med (Lausanne). 2021;8:680540.
Binder NB, Depasse F, Mueller J, et al. Clinical use of thrombin generation assays. J Thromb Haemost. 2021;19:2918–2929.
Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287–291.
Grottke O, Rossaint R, Henskens Y, van Oerle R, Ten Cate H, Spronk HM. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One. 2013;8:e64100.
Lang T, Bauters A, Braun SL, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis. 2005;16:301–310.
Bachler M, Bösch J, Stürzel DP, et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth. 2021;126:590–598.
Dunbar NM, Chandler WL. Thrombin generation in trauma patients. Transfusion. 2009;49:2652–2660.
Park MS, Spears GM, Bailey KR, et al. Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: a prospective cohort study. J Trauma Acute Care Surg. 2017;83:381–387.
Schöchl H, Voelckel W, Maegele M, Kirchmair L, Schlimp CJ. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. Crit Care. 2014;18:R147.
David JS, Levrat A, Inaba K, et al. Utility of a point-of-care device for rapid determination of prothrombin time in trauma patients: a preliminary study. J Trauma Acute Care Surg. 2012;72:703–707.
Ng KF. Changes in thrombelastograph variables associated with aging. Anesth Analg. 2004;99:449–454.
Ponschab M, Voelckel W, Pavelka M, Schlimp CJ, Schöchl H. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma. Scand J Trauma Resusc Emerg Med. 2015;23:84.
Groene P, Wiederkehr T, Kammerer T, et al. Comparison of two different fibrinogen concentrates in an in vitro model of dilutional coagulopathy. Transfus Med Hemother. 2020;47:167–174.
Haas T, Fries D, Velik-Salchner C, Reif C, Klingler A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg. 2008;106:1360–1365.
Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S. Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. Br J Anaesth. 2012;109:376–381.
Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021;47:49–59.
Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4:e258–e271.
Schöchl H, Schlimp CJ. Trauma bleeding management: the concept of goal-directed primary care. Anesth Analg. 2014;119:1064–1073.
Stein P, Kaserer A, Spahn GH, Spahn DR. Point-of-care coagulation monitoring in trauma patients. Semin Thromb Hemost. 2017;43:367–374.
Schäfer N, Driessen A, Bauerfeind U, et al. In vitro effects of different sources of fibrinogen supplementation on clot initiation and stability in a model of dilutional coagulopathy. Transfus Med. 2016;26:373–380.
Ziegler B, Bachler M, Haberfellner H, et al.; FIinTIC study group. Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): a multicentre, double-blind, placebo-controlled, randomised pilot study. Eur J Anaesthesiol. 2021;38:348–357.